◎ Sugi Atlas

Atlas / Drug / Ipilimumab

Ipilimumab

drug
On this page

Also known as BMS-734016BMS734016MDX-010MDX-010 MDX-CTLA4MDX-101MDX-CTLA-4MDX010Yervoy

Summary

Ipilimumab (CHEMBL1789844) is an approved antibody (ATC L01FX04) targeting CTLA4; indicated across 111 conditions including melanoma and metastatic melanoma; with CIViC clinical evidence for 7 variant-indication associations (e.g. CD274 Expression in melanoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FX04
  • Targets: 1 (CTLA4)
  • Indications: 111 conditions
  • Clinical trials: 753
  • Precision-oncology evidence (CIViC): 7 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1789844
NameIpilimumab
TypeAntibody
Max phase4
ATCL01FX04

Also known as: BMS-734016, BMS734016, Ipilimumab, MDX-010, MDX-010 MDX-CTLA4, MDX-101, MDX-CTLA-4, MDX010, Yervoy, IPILIMUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CTLA4cytotoxic T-lymphocyte-associated protein 4 (CD152)Binding8.070%P16410

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CTLA4.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Co-stimulation by CD281CTLA4
Co-inhibition by CTLA41CTLA4
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)1CTLA4

Dominant GO biological processes

GO termTargets
adaptive immune response1
immune response1
DNA damage response1
negative regulation of B cell proliferation1
negative regulation of T cell proliferation1
positive regulation of apoptotic process1
negative regulation of regulatory T cell differentiation1
T cell receptor signaling pathway1
B cell receptor signaling pathway1
negative regulation of T cell receptor signaling pathway1
negative regulation of T cell activation1
immune system process1
regulation of T cell proliferation1

Indications & clinical

Indications

111 indications (15 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
melanoma4MONDO:0005105EFO:0000756
metastatic melanoma4MONDO:0005191EFO:0002617
non-small cell lung carcinoma4MONDO:0005233EFO:0003060
neoplasm4MONDO:0005070EFO:0000616
cutaneous melanoma4MONDO:0005012EFO:0000389
clear cell renal carcinoma4MONDO:0005005EFO:0000349
renal cell carcinoma4MONDO:0005086EFO:0000681
colorectal carcinoma4MONDO:0024331EFO:1001951
colorectal adenocarcinoma4MONDO:0005008EFO:0000365
colorectal neoplasm4MONDO:0005335EFO:0004142
malignant mesothelioma4MONDO:0006292EFO:1000355
renal carcinoma4MONDO:0005206EFO:0002890
renal cell adenocarcinoma4MONDO:0005549EFO:0005708
small cell lung carcinoma3MONDO:0008433EFO:0000702
gastric adenocarcinoma3MONDO:0005036EFO:0000503
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
hepatocellular carcinoma3MONDO:0007256EFO:0000182
glioblastoma3MONDO:0018177EFO:0000519
mesothelioma3MONDO:0005065EFO:0000588
sarcoma3MONDO:0005089EFO:0000691
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
upper aerodigestive tract neoplasm3MONDO:0005398EFO:0004284
head and neck cancer3MONDO:0005627EFO:0006859
soft tissue sarcoma3MONDO:0018078EFO:1001968
gastric neoplasm3MONDO:0021085MONDO:0001056
kidney cancer3MONDO:0002367MONDO:0002367
lung neoplasm3MONDO:0021117MONDO:0008903
squamous cell carcinoma3MONDO:0005096EFO:0000707
kidney neoplasm3MONDO:0021163EFO:0003865
carcinoma2MONDO:0004993EFO:0000313
prostate carcinoma2MONDO:0005159EFO:0001663
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
prostate adenocarcinoma2MONDO:0005082EFO:0000673
breast carcinoma2MONDO:0004989EFO:0000305
cutaneous neuroendocrine carcinoma2MONDO:0019210EFO:1001471
Hodgkins lymphoma2MONDO:0004952EFO:0000183
adenocarcinoma2MONDO:0004970EFO:0000228
Kaposi’s sarcoma2MONDO:0005055EFO:0000558
ovarian carcinoma2MONDO:0005140EFO:0001075
synovial sarcoma2MONDO:0010434EFO:0001376
carcinoma of esophagus2MONDO:0019086EFO:0002916
biliary tract neoplasm2MONDO:0005304EFO:0003891
inflammatory breast carcinoma2MONDO:0006804EFO:1000984
gliosarcoma2MONDO:0016681EFO:1001465
colon carcinoma2MONDO:0002032EFO:1001950
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
lung adenocarcinoma2MONDO:0005061EFO:0000571
cervical carcinoma2MONDO:0005131EFO:0001061
dedifferentiated liposarcoma2MONDO:0020563EFO:0003085
basal cell carcinoma2MONDO:0020804EFO:0004193
urothelial carcinoma2MONDO:0040679EFO:0008528
rectal cancer2MONDO:0006519EFO:1000657
undifferentiated pleomorphic sarcoma2MONDO:0002142EFO:1001972
carcinoid tumor2MONDO:0005369EFO:0004243
uterine carcinosarcoma2MONDO:0006485EFO:1000613
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
salivary gland cancer2MONDO:0004669MONDO:0004669
breast neoplasm2MONDO:0021100MONDO:0007254
ovarian cancer2MONDO:0008170MONDO:0008170
meningioma2MONDO:0016642MONDO:0020634
small cell carcinoma2MONDO:0000402EFO:0008524
cervical adenocarcinoma2MONDO:0005153EFO:0001416
colonic neoplasm2MONDO:0005401EFO:0004288
nevoid basal cell carcinoma syndrome2MONDO:0007187MONDO:0007187
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
leiomyosarcoma2MONDO:0005058EFO:0000564
ocular melanoma2MONDO:0006325EFO:1000403
uveal melanoma2MONDO:0006486EFO:1000616
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
chronic myeloid leukemia1MONDO:0011996EFO:0000339
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
neoplasm of mature B-cells1MONDO:0004949EFO:0000096
myelodysplastic syndrome1MONDO:0018881EFO:0000198
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
acute myeloid leukemia1MONDO:0018874EFO:0000222
diffuse large B-cell lymphoma1MONDO:0018905EFO:0000403
lymphoma1MONDO:0005062EFO:0000574
HIV infectious disease1MONDO:0005109EFO:0000764
plasma cell myeloma1MONDO:0009693EFO:0001378
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
retroperitoneal cancer1MONDO:0005941EFO:0007466
metastatic neoplasm1MONDO:0024883EFO:0009709
fallopian tube carcinoma1MONDO:0006206EFO:1000251
endometrial carcinoma1MONDO:0002447EFO:1001512
neuroblastoma1MONDO:0005072EFO:0000621
peritoneal neoplasm1MONDO:0006901MONDO:0002087
nerve sheath neoplasm1MONDO:0002547MONDO:0002547
glioma1MONDO:0021042MONDO:0100342
skin neoplasm1MONDO:0002531MONDO:0002898
endometrium neoplasm1MONDO:0021251MONDO:0011962
cholangiocarcinoma1MONDO:0019087EFO:0005221
triple-negative breast carcinoma1MONDO:0005494EFO:0005537
leukemia1MONDO:0005059EFO:0000565
myeloid leukemia1MONDO:0004643MONDO:0004643
pancreatic ductal adenocarcinoma1MONDO:0005184MONDO:0005184

13 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 753.

Phase distribution

PhaseTrials
PHASE2329
PHASE1190
PHASE1/PHASE2115
PHASE364
Not specified29
PHASE2/PHASE310
EARLY_PHASE110
PHASE46

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02068196PHASE4ACTIVE_NOT_RECRUITINGA National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT07504796PHASE4RECRUITINGctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NCT01856023PHASE4TERMINATEDHD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
NCT02982954PHASE4COMPLETEDA Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
NCT04513522PHASE4COMPLETEDA Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
NCT01274338PHASE3ACTIVE_NOT_RECRUITINGIpilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT02224781PHASE3ACTIVE_NOT_RECRUITINGDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02339571PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02506153PHASE3ACTIVE_NOT_RECRUITINGPhysician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02785952PHASE3ACTIVE_NOT_RECRUITINGLung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT03036098PHASE3ACTIVE_NOT_RECRUITINGStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03141177PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03391869PHASE3ACTIVE_NOT_RECRUITINGNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
NCT03793166PHASE3ACTIVE_NOT_RECRUITINGImmunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03873402PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03937219PHASE3ACTIVE_NOT_RECRUITINGStudy of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT04008030PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04039607PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
NCT05141721PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
NCT05144854PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT05987332PHASE2/PHASE3ACTIVE_NOT_RECRUITINGIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT06097728PHASE3RECRUITINGMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06364631PHASE3RECRUITINGCARE1 Pragmatic Clinical Trial
NCT06490536PHASE3RECRUITINGThe Sagittarius Trial
NCT06581406PHASE2/PHASE3RECRUITINGA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06743126PHASE3RECRUITINGSUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06794775PHASE3RECRUITINGSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
NCT07000149PHASE3ACTIVE_NOT_RECRUITINGA Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
NCT07166406PHASE3RECRUITINGTesting Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07338981PHASE3NOT_YET_RECRUITINGThe Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
NCT07383441PHASE3NOT_YET_RECRUITINGAdding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
NCT00094653PHASE3COMPLETEDMDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
NCT00324155PHASE3COMPLETEDDacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
NCT00636168PHASE3COMPLETEDEfficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
NCT00861614PHASE3COMPLETEDStudy of Immunotherapy to Treat Advanced Prostate Cancer
NCT01057810PHASE3COMPLETEDPhase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
NCT01285609PHASE3COMPLETEDPhase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
NCT01450761PHASE3COMPLETEDTrial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
NCT01515189PHASE3COMPLETEDPhase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Clinical evidence (CIViC)

Variant × indication × effect (7 predictive associations from 7 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
CD274 ExpressionMelanomaSensitivity/ResponseIpilimumab + NivolumabCIViC BEID1615
NRAS Q61HMelanomaSensitivity/ResponseIpilimumabCIViC BEID7333
PBRM1 Loss-of-functionRenal Cell CarcinomaSensitivity/ResponseIpilimumabCIViC BEID7301
TMB HighMelanomaSensitivity/ResponseIpilimumabCIViC BEID12036
MDM2 AmplificationCancerAdverse ResponseNivolumab + Pembrolizumab + IpilimumabCIViC BEID2916
CTLA4::CD28 FusionSezary’s DiseaseSensitivity/ResponseIpilimumabCIViC CEID1520
IFNGR1 LossMelanomaResistanceIpilimumabCIViC DEID12142

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot